13626-59-0

Basic information

• Product Name: 3-METHOXY-ISOXAZOLE-5-CARBOXYLIC ACID
• Synonyms: 3-METHOXY-ISOXAZOLE-5-CARBOXYLIC ACID;5-Isoxazolecarboxylic acid, 3-Methoxy-
• CAS NO: 13626-59-0
• Molecular Formula: C₅H₅NO₄
• Molecular Weight: 143.1
• Product Categories: Heterocycles series;Building Blocks;Carboxy;Isoxazole
• Mol File: 13626-59-0.mol

Chemical Properties

• Boiling Point: 348.6 °C at 760 mmHg
• Flash Point: 164.6 °C
• Appearance: /
• Density: 1.403 g/cm³
• Vapor Pressure: 1.87E-05mmHg at 25°C
• Refractive Index: 1.505
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-METHOXY-ISOXAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-ISOXAZOLE-5-CARBOXYLIC ACID(13626-59-0)
• EPA Substance Registry System: 3-METHOXY-ISOXAZOLE-5-CARBOXYLIC ACID(13626-59-0)

Safety Data

• Hazardous Substances Data: 13626-59-0(Hazardous Substances Data)

Usage

Uses

3-Methoxyisoxazole-5-carboxylic acid

InChI:InChI=1/C5H5NO4/c1-9-4-2-3(5(7)8)10-6-4/h2H,1H3,(H,7,8)

Upstream product

• 67-56-1 methanol 
• 6567-35-7 3-bromo-5-isoxazolecarboxylic acid 
• 77-78-1 dimethyl sulfate 
• 10068-07-2 methyl 3-hydroxy-5-isoxazolecarboxylate 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 74-88-4 methyl iodide 
• 16880-11-8 3-methoxyisoxazole-5-carboxylic acid methyl ester 
• 20724-56-5 3-chloro-5-isoxazolecarboxylic acid 

Downstream Products

• 16880-11-8 3-methoxyisoxazole-5-carboxylic acid methyl ester 
• 2763-94-2 5-aminomethyl-3-methoxyisoxazole 
• 1217794-37-0 C₂₄H₂₁ClF₂N₆O₅ 
• 1217794-38-1 C₂₃H₂₀ClF₂N₇O₅ 
• 1217794-39-2 C₂₃H₂₁ClF₂N₈O₄ 
• 1217794-40-5 C₂₂H₂₀ClF₂N₉O₄ 
• 1217794-41-6 C₂₃H₂₂ClF₂N₉O₄ 
• 916922-05-9 C₁₁H₁₅NO₄S 
• 1259568-39-2 C₂₄H₂₂FN₅O₄ 
• 1259568-41-6 C₂₄H₂₁ClFN₅O₄ 
• 1259568-89-2 C₂₄H₂₁BrFN₅O₄ 
• 1259568-93-8 C₂₄H₂₂FN₅O₅ 
• 1313389-13-7 3-benzyl-1,6-dihydro-8-(3-methoxyisoxazol-5-yl)-6-thioxo-3H-purin-2(7H)-one 
• 1313389-23-9 3-benzyl-8-(3-methoxyisoxazol-5-yl)-6-(methylthio)-3H-purin-2(7H)-one 

Relevant articles and documents

Structure-activity studies of 6-substituted decahydroisoquinoline-3- carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity

We have explored the excitatory amino acid antagonist activity in a series of decahydroisoquinoline-3-carboxyic acids, and within this series found the potent and selective AMPA antagonist (3SR,4aRS,6RS,8aRS)-6-(2-(1H-tetrazol- 5-yl)ethyl)decahydroisoquin

NEW BIARYL AMIDE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.

NEW BIARYL AMIDE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.

New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists

A series of 4-allyl/benzyl-7,8-dihydro-8-methyl/ethyl-2-[(substituted) isoxazol/pyrazol-3/5-yl]-1H-imidazo[2,1-i]purin-5(4H)-ones has been synthesized and evaluated in radioligand binding assays to determine their affinities at the human A1, A

Practical synthesis of a potent bradykinin B1 antagonist via enantioselective hydrogenation of a pyridyl N-acyl enamide

(Chemical Equation Presented) A practical and efficient synthesis of bradykinin B1 antagonist 1 is described. A convergent strategy was utilized which involved synthesis of three fragments: 3, 6, and 7. Cross coupling of fragments 6 and 7 followed by amidation with 3 enabled efficient synthesis of 1 in 19 steps total, a 35% overall yield from commercially available pyridine 10. The key to the success of the synthesis was the development of a fluorodenitration step to install the fluorine in pyridine 7 and a catalytic enantioselective hydrogenation of N-acyl enamide 9 to set the stereochemistry.

HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY

Disclosed is a compound useful as a type I 11 β hydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted cycloalkyl, optionally su